Bone News and Research

RSS

Shenzhen Beike Biotechnology forms joint venture with SiriCell Technologies

Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Most of the time, the body's blood-forming (hematopoietic) stem cells remain dormant, with just a few producing blood cells and maintaining a balance among the different types.

10 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Curexo Technology's ROBODOC assists in first commercial hip replacement surgery

Curexo Technology Corporation made history on Wednesday, May 26, 2010 when its next-generation ROBODOC® Surgical System assisted Dr. William Bargar as he performed the first commercial hip replacement surgery on Warren Roberts of Davis, CA. Mr. Roberts had his left hip replacement using this robotic device in 1995 as a part of an FDA study. This recent surgery performed at Sutter General in Sacramento was for Mr. Roberts' right hip.

10 Jun 2010

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.

9 Jun 2010

Surgery through eyelids avoid major head trauma

Surgeons at Johns Hopkins have safely and effectively operated inside the brains of a dozen patients by making a small entry incision through the natural creases of an eyelid to reach the skull and deep brain.

9 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Young girls who drink soda have less healthy diets through adolescence than their peers who do not drink soda, according to a Penn State study. The ten-year study showed that girls who drank soda at age five had diets that were less likely to meet nutritional standards for the duration of the study, which ended at age 15. Girls who did not drink soda at age five did not meet certain nutritional requirements, but their diets were healthier.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

GTx reports positive results from toremifene Phase III clinical trial

GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

8 Jun 2010

$UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study$

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

A new study shows that umbilical cord mesenchymal stem cell transplant may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus.

8 Jun 2010

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.

8 Jun 2010

Augmentation with Wright's GRAFTJACKET Matrix improves repair healing for large rotator cuff tears

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that results of a prospective, randomized controlled clinical study evaluating biologic augmentation of challenging arthroscopic rotator cuff repairs with GRAFTJACKET® Matrix were presented by F. Alan Barber, MD at the recent Arthroscopy Association of North America (AANA) annual meeting.

8 Jun 2010

Scientists combine two agents to treat patients with multiple myeloma

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data showing that by combining two treatment agents in the care of multiple myeloma patients, doctors can use higher dosages of chemotherapy before autologous stem cell transplant while alleviating painful and debilitating side effects like severe oral mucositis (mouth ulcers).

8 Jun 2010

$Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL$

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences Inc.,, today announced complete data from its pivotal, Phase 2 RALLY clinical trial for Marqibo® (vincristine sulfate liposome injection) for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Results from the RALLY trial demonstrated compelling evidence of single-agent, anti-leukemic activity in an advanced, heavily pre-treated, adult ALL population.

8 Jun 2010

Bone News and Research

Shenzhen Beike Biotechnology forms joint venture with SiriCell Technologies

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Nativis awarded patents in Japan, China, India for drug signal technology

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Curexo Technology's ROBODOC assists in first commercial hip replacement surgery

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Surgery through eyelids avoid major head trauma

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Some commonly used drugs cause bone loss: New research

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Blood vessel-blocking drug slows prostate cancer progression: Experts

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

GTx reports positive results from toremifene Phase III clinical trial

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

USPTO grants ISCO patent to International Stem Cell's hpSC

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Augmentation with Wright's GRAFTJACKET Matrix improves repair healing for large rotator cuff tears

Scientists combine two agents to treat patients with multiple myeloma

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News